5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The market is segmented by Route of Administration, Mode of NDDS (Targeted Drug Delivery Systems, Controlled Drug Delivery Systems, and Modulated Drug Delivery Systems), and Geography
The major factors that are driving growth in the European novel drug delivery system market are technological advancements promoting the development of NDDS and the rising need for controlled release of drugs.
Nowadays, for the treatment of chronic disorders as well as for controlling the release of active ingredients from drug products, a unique delivery system, the controlled release drug delivery system (CRDDS) of novel drug delivery, is included in the drug delivery technique. Majority of the active pharmaceutical ingredients are distributed in the form of CRDDS. A controlled drug delivery system is, thus, a very reliable, potential form of novel drug delivery technique, in which the drug is subjected to the appropriate pharmaceutical drug dosage form and its release is predetermined, making the release controlled at particular sites of action (cells, tissues, and organs).
Transdermal patches, implants, nasal systems, microcapsules, etc., are some of the common systems that are considered under controlled release systems. The need for controlled release of drugs is propelling the increasing demand for unique and innovative systems for drug delivery, where this novel drug delivery system plays a significant role in the advancement of controlled release of drugs, thereby driving the growth of the market, over the forecast period.
As per the scope of this report, novel drug delivery system refers to the approaches, technologies, systems, and formulations for transporting a pharmaceutical compound in the body as required to safely achieve its desired therapeutic effects. It is a novel system for the delivery of drugs, different from the conventional drug delivery systems. The market is segmented by route of administration, mode of NDDS, and geography.
|By Route of Administration|
|Oral Drug Delivery Systems|
|Injectable Drug Delivery Systems|
|Pulmonary Drug Delivery Systems|
|Transdermal Drug Delivery Systems|
|Other Routes of Administration|
|By Mode of NDDS|
|Targeted Drug Delivery Systems|
|Controlled Drug Delivery Systems|
|Modulated Drug Delivery Systems|
Report scope can be customized per your requirements. Click here.
The targeted drug delivery system segment is expected to hold the largest share in the market owing to the benefits associated with it. Targeted drug delivery is a mixture of controlled drug delivery and sustained drug delivery systems. This method of administration of drugs assures greater efficacy, owing to the higher concentration of the drug at the target area in the body.
In the targeted drug delivery system, the drug, which is released at the site of action, then gets attached to the diseased tissue. One of the prime benefits of this mode of drug delivery is controlled and protected action, as the slow, prolonged action of the drug on the diseased tissue for an adequate period of treatment time is expected to provide potential benefits. These benefits of targeted drug delivery, coupled with the increasing need for technological advancements and a rising need for higher efficacy, owing to the increasing burden of chronic diseases, are propelling the growth of the segment.
To understand key trends, Download Sample Report
The market comprises major market players who are primarily focused on research and development for the creation of a stable and safe formulation. The market has been experiencing technological developments on a large scale for the past couple of years. Some of the market players are Abbott Laboratories, AstraZeneca PLC, Bayer AG, GlaxoSmithKline PLC, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche AG, and Sanofi SA.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Technological Advancements Promoting the Development of NDDS
4.2.2 Rising Need for the Controlled Release of Drugs
4.3 Market Restraints
4.3.1 Stringent Regulatory Guidelines
4.3.2 Stability Issues
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Route of Administration
5.1.1 Oral Drug Delivery Systems
5.1.2 Injectable Drug Delivery Systems
5.1.3 Pulmonary Drug Delivery Systems
5.1.4 Transdermal Drug Delivery Systems
5.1.5 Other Routes of Administration
5.2 By Mode of NDDS
5.2.1 Targeted Drug Delivery Systems
5.2.2 Controlled Drug Delivery Systems
5.2.3 Modulated Drug Delivery Systems
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 AstraZeneca PLC
6.1.3 Bayer AG
6.1.4 GlaxoSmithKline PLC
6.1.5 Johnson & Johnson
6.1.6 Merck & Co. Inc.
6.1.7 Novartis AG
6.1.8 Pfizer Inc.
6.1.9 F. Hoffmann-La Roche AG
6.1.10 Sanofi SA
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments